Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis

PLoS One. 2019 Oct 17;14(10):e0223308. doi: 10.1371/journal.pone.0223308. eCollection 2019.

Abstract

South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Coinfection
  • Diarylquinolines / administration & dosage
  • Diarylquinolines / therapeutic use*
  • Drug Substitution*
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Retreatment
  • Retrospective Studies
  • Rifampin / therapeutic use
  • South Africa
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / microbiology*

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • bedaquiline
  • Rifampin